Ono Pharmaceuticals

Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of “Dedicated to the Fight against Disease and Pain,” Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organisations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at https://www.ono-pharma.com/en.

In 2023, UK DRI and Ono Pharmaceutical Co., Ltd. (Ono) launched a funding initiative to support early-stage translational therapeutics in neurodegeneration. The partnership supports postdoctoral research-level projects to undertake novel target identification in a UK DRI research group. This collaboration benefits from the expertise in neurodegenerative diseases held at the UK DRI and in-kind support from the state-of-the-art facilities from the institute, as well as Ono’s internal capabilities in several drug modalities and the company’s expertise in bringing therapeutic programs into the public use. The partnership kicked-off with two projects to study novel pathways and targets in AD and mitochondrial diseases, respectively. In October 2025, we extended the partnership adding a third project to explore a novel target in ALS.